• Anette Zawinell
  • Ulrich Schwabe


Größte Gruppe der Antiallergika sind die wenig sedierenden H1-Antihistaminika, die vor allem zur Behandlung des Heuschnupfens, der allergischen Bindehautentzündung und der Urtikaria eingesetzt werden.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson M, Puy R, Weiner J (2003): Allergen immunotherapy for asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.Google Scholar
  2. Adelsberg BR (1997): Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 157:494–500.PubMedCrossRefGoogle Scholar
  3. Adkinson NF, Eggleston PA, Eney D, Goldstein EO, Schuberth KC et al. (1997): A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336:324–331.PubMedCrossRefGoogle Scholar
  4. Arvidsson MB, Löwhagen O, Rak S (2002): Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 109: 777–783.PubMedCrossRefGoogle Scholar
  5. Austen KF (2001): Allergies, anaphylaxis, and systemic mastocytosis. In: Braunwald E et al. (eds): Harrison’s principles of internal medicine. McGraw-Hill Medical Publishing Division, New York, pp. 1913–1922.Google Scholar
  6. Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, Wichel FB (1988): Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 82: 971–977.PubMedCrossRefGoogle Scholar
  7. Bousquet J, Scheinmann P, Guinnepain MT, Petrin-Fayolle M, Sauvaget J, Tonnel AB et al. (1999): Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54: 249–260.PubMedCrossRefGoogle Scholar
  8. Canonica GW, Passalacqua G (2003): Noninjection routes for immunotherapy. J Allerg Clin Immunol 111: 437–448.CrossRefGoogle Scholar
  9. Day JH, Briscoe M, Widlitz MD (1998): Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. Allergy Clin Immunol 101: 638–645.CrossRefGoogle Scholar
  10. Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brian F, Noble W et al. (1999): Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341: 468–475.PubMedCrossRefGoogle Scholar
  11. Fricke U, Schwabe U (2004): Neue Arzneimittel. In Schwabe U, Paffrath D (Hrsg): Arzneiverordnungs-Report 2003. Springer-Verlag, Berlin u. a., S. 24–87.CrossRefGoogle Scholar
  12. Frossard N, Lacronique J, Melac M, Benabdesselam O, Bran JJ et al. (1997): Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 52: 205–209.PubMedCrossRefGoogle Scholar
  13. Guez S, Vatrinet C, Fadel R, Andre C (2000): House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55: 369–375.PubMedCrossRefGoogle Scholar
  14. Hoff M, Krail M, Kästner M, Haustein D, Vieths S (2002): Fusarium culmorum causes strong degradation of pollen allergens in extract mixtures. J Allergy Clin Immunol 109:96–101.PubMedCrossRefGoogle Scholar
  15. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM (1978): A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299:157–161.PubMedCrossRefGoogle Scholar
  16. Lüderitz-Püchel U, May S, Haustein D (1996): Zwischenfälle nach Hyposensibilisierung. Münch Med Wschr 138:129–132.Google Scholar
  17. Mellerup MT, Hahn GW, Poulsen LK, Mailing HJ (2000): Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induciton treatment. Clin Exp Allergy. 30:1423–1429.PubMedCrossRefGoogle Scholar
  18. Meltzer EO, Weiler JM, Widlitz MD (1996): Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 97: 617–626.PubMedCrossRefGoogle Scholar
  19. Möller C, Dreborg S, Ferdousi HA, Halken S, H0st A, Jacobsen L et al. (2002): Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109: 251–256.PubMedCrossRefGoogle Scholar
  20. Olsen OT, Larsen KR, Jacobsan L, Svedsen UG (1997): A 1-year placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52: 853–859.PubMedCrossRefGoogle Scholar
  21. O’Neill SM, Forsyth A (1988): Urticaria. Prescribers J 28:14–20.Google Scholar
  22. Petersen BN, Janniche H, Munch EP, Wihl JA, Bowadt H, Ipsen H, Lowenstein H (1988): Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 43: 353–362.PubMedCrossRefGoogle Scholar
  23. Pichler CE, Helbling A, Pichler WJ (2001): Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56: 301–306.PubMedCrossRefGoogle Scholar
  24. Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ (1997): Specific immunotherapy with Dermatophagoides ptheronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52: 274–283.PubMedCrossRefGoogle Scholar
  25. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA (1993): Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 92: 6–15.PubMedCrossRefGoogle Scholar
  26. Routledge PA, Lindquist M, Edwards IR (1999): Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 29(Suppl 3): 240–246.PubMedCrossRefGoogle Scholar
  27. Ruëff F, Wenderoth A, Przybilla B (2001): Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108:1027–1032.PubMedCrossRefGoogle Scholar
  28. Spencer CM, Faulds D, Peters DH (1993): Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46: 1055–80.PubMedCrossRefGoogle Scholar
  29. Warner JO, Price JF, Soothill JF, Hey EN (1978): Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2: 912–915.PubMedCrossRefGoogle Scholar
  30. WHO Position Paper (1998): Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl 1): 1–42.Google Scholar
  31. Wilson DR, Torres LI, Durham SR. (2003): Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Anette Zawinell
    • 1
  • Ulrich Schwabe
    • 2
  1. 1.Wissenschaftliches Institut der AOKBonn
  2. 2.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations